The Effect of the Angiotensin-Converting Enzyme Inhibitor Perindopril on the Lipid Status of Rattus Norvegicus (Berkenhout 1769)

被引:0
|
作者
Haskovic, Elma [1 ]
Dolicanin, Azra [2 ,3 ]
Haskovic, Edhem [2 ,3 ]
Herenda, Safija
Lepara, Orhan [4 ]
机构
[1] Univ Sarajevo, Fac Pharm, Zmaja Od Bosne 8, Sarajevo 71000, Bosnia & Herceg
[2] Univ Sarajevo, Fac Sci, Dept Biol, Zmaja Od Bosne 33-35, Sarajevo 71000, Bosnia & Herceg
[3] Univ Sarajevo, Fac Sci, Dept Chem, Zmaja Od Bosne 33-35, Sarajevo 71000, Bosnia & Herceg
[4] Univ Sarajevo, Fac Med, Cekalusa 90, Sarajevo 71000, Bosnia & Herceg
来源
MEDICON 2023 AND CMBEBIH 2023, VOL 1 | 2024年 / 93卷
关键词
Perindopril; In vivo studies; Lipid profile; CHOLESTEROL RATIO; HDL-CHOLESTEROL; DRUGS;
D O I
10.1007/978-3-031-49062-0_39
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Angiotensin-converting enzyme (ACE) inhibitors are an important group of drugs that are widely used in the treatment of hypertension and congestive heart failure. Perindopril is an ester-inactive form of the angiotensin-converting inhibitor perindoprilat. Compared to other an- giotensin-converting enzyme inhibitors, perindopril has a higher affinity and lipophilicity. The aim of this work was to investigate the effect of the angiotensin-converting enzyme inhibitor, perindopril, on the lipid status of Rattus norvegicus (Berkenhout 1769), Wistar strain. After four days of subcutaneous application of perindopril in individuals of the species Rattus norvegicus, changes in the concentration of the investigated parameters were recorded. The individuals were divided into two experimental groups of 10 individuals each. Individuals of the first experimental group were administered an aqueous solution of perindopril at a concentration of 0.8 mg/kg, while individuals of the second experimental group were administered perindopril at a concentration of 1.6 mg/kg of body weight. By mutual comparison of the results obtained between the two experimental groups, it can be concluded that there was a change in the concentration of all tested parameters, and there is also a difference in the values of the tested parameters of the lipid profile in both tested groups compared to reference literature data (total cholesterol (UH) 2.95 mmol/l, triglycerides (Tg) 0.86 mmol/l, HDL-cholesterol 1.27 mmol/l, LDL-cholesterol 1.28 mmol/l and VLDL cholesterol 0.39 mmol/l, with the difference being greater in the group with a higher applied dose.
引用
收藏
页码:353 / 367
页数:15
相关论文
共 50 条
  • [21] DOSE ANTIHYPERTENSIVE EFFECT RELATIONSHIP FOR THE ANGIOTENSIN CONVERTING-ENZYME-INHIBITOR - PERINDOPRIL
    FRANCES, Y
    SCHWAB, C
    LUCCIONI, R
    CLINICAL AND EXPERIMENTAL HYPERTENSION PART A-THEORY AND PRACTICE, 1986, 8 (01) : 147 - 148
  • [22] ESSENTIAL HYPERTENSION - EFFECT OF AN ORAL INHIBITOR OF ANGIOTENSIN-CONVERTING ENZYME
    MACGREGOR, GA
    MARKANDU, ND
    ROULSTON, JE
    JONES, JC
    BRITISH MEDICAL JOURNAL, 1979, 2 (6198): : 1106 - 1109
  • [23] Murine Recombinant Angiotensin-Converting Enzyme 2 Effect on Angiotensin II-Dependent Hypertension and Distinctive Angiotensin-Converting Enzyme 2 Inhibitor Characteristics on Rodent and Human Angiotensin-Converting Enzyme 2
    Ye, Minghao
    Wysocki, Jan
    Gonzalez-Pacheco, Francisco R.
    Salem, Mahmoud
    Evora, Karla
    Garcia-Halpin, Laura
    Poglitsch, Marko
    Schuster, Manfred
    Batlle, Daniel
    HYPERTENSION, 2012, 60 (03) : 730 - +
  • [24] Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease
    Yamada, Koji
    Uchida, Shinichi
    Takahashi, Syusuke
    Takayama, Makoto
    Nagata, Yoshinori
    Suzuki, Nobuyuki
    Shirakura, Shiro
    Kanda, Tomoyuki
    BRAIN RESEARCH, 2010, 1352 : 176 - 186
  • [25] INHIBITOR BINDING ASSAY FOR ANGIOTENSIN-CONVERTING ENZYME
    FYHRQUIST, F
    TIKKANEN, I
    GRONHAGENRISKA, C
    HORTLING, L
    HICHENS, M
    CLINICAL CHEMISTRY, 1984, 30 (05) : 696 - 700
  • [26] Angiotensin-converting enzyme inhibitor renography.
    Rehm, PK
    AMERICAN JOURNAL OF ROENTGENOLOGY, 1996, 166 (02) : 458 - 459
  • [27] Angiotensin-converting enzyme inhibitor and fetal nephromegaly
    Michel, C.
    Simon, E.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2022, 50 (06): : 497 - 498
  • [28] ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR FETOPATHY
    PRYDE, PG
    SEDMAN, AB
    NUGENT, CE
    BARR, M
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1993, 3 (09): : 1575 - 1582
  • [29] ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR THERAPY
    OPIE, LH
    PRZYBOJEWSKI, JZ
    SOUTH AFRICAN MEDICAL JOURNAL, 1992, 81 (04): : 183 - 185
  • [30] CAPTOPRIL - ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR
    KOCH, H
    PHARMACY INTERNATIONAL, 1981, 2 (08): : 164 - 165